Building access to the Regenstrief Institute is restricted through early 2021. More on our coronavirus precautions.
See our coronavirus precautions.
Patient on life support in ICU

A new study shows that critically ill patients are not benefitting from antipsychotic medications that doctors have been using to treat delirium in patients in intensive care units. The evidence suggests doctors may need to re-examine the practice. Regenstrief investigator Babar Khan, M.D., was a co-author on the study.

Each year, more than seven million hospitalized patients in the United States develop delirium. The acute brain failure results in confusion and long-term memory problems.

The large study, MIND-USA (Modifying the INcidence of Delirium), sought to answer whether typical and atypical antipsychotics — haloperidol or ziprasidone — affected delirium, survival, length of stay or safety in ICU patients. Researchers screened nearly 21,000 patients at 16 U.S. medical centers. Of the 1,183 patients on mechanical ventilation or in shock, 566 became delirious and were randomized into groups receiving either intravenous haloperidol, ziprasidone or placebo (saline). Results showed that patients who received the drugs did not experience any improvements whatsoever in delirium, coma, length of stay or survival.

Study authors say the medicines are bringing risk and cost without benefit, based on the outcomes measured in this study. Doctors have been prescribing the drugs for 40 years.

Dr. Khan, who worked on this study, has conducted extensive studies on treating and preventing delirium. He led a project at Regenstrief that developed and validated the Confusion Assessment Method for the Intensive Care Unit 7. It’s an easy-to-use method to determine the severity of delirium.

The MIND-USA study was published in the New England Journal of Medicine. It was funded by the National Institute on Aging.

Related News

Feb 26, 2021 • News
National Coordinator for Health Information Technology to deliver keynote at LOINC virtual conference
LOINC® at Regenstrief Institute, a global standard for health terminology, is hosting its semi-annual conference March 9-12, 2021. Micky Tripathi, PhD, the national coordinator for health information technology at the U.S. Department of Health and Human Services will deliver the keynote address during the 4-day virtual event.  LOINC, which stands for Logical Observation Identifiers Names and Codes, is a standard for identifying health measurements, observations, and documents. Created and…
Continue Reading >
Feb 26, 2021 • News
New ONC, NLM funding supports data exchange and response to COVID-19 pandemic
LOINC® at Regenstrief, an international health data standard critical to health information exchange, has received additional federal funding to support efforts to respond to the COVID-19 pandemic and future public health needs. The funding, expected to total about $2 million, is from the Office of the National Coordinator for Health Information Technology (ONC) and the National…
Continue Reading >